Idorsia is the new, independent company listed since June 16th on SIX Swiss Exchange . The company is born from the transfer of the Actelion’s and early stage clinical pipeline business, with the goal of develop the new company into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. “We are off to a great start with the recent results with aprocitentan and cenerimod and are eagerly awaiting key results for our dual orexin receptor antagonist in the coming months. Beyond that we will be taking decisions on our Phase 1 pipeline assets before the end of the year, so we have a lot to look forward to”, commented Jean-Paul Clozel, CEO of Idorsia.